tbuckley/cabot-search huggingface dataset:
Sacroiliac Joint Ankylosis in Young Spondyloarthritis Patients Receiving Biologic Therapy: Observation of Serial Magnetic Resonance Imaging Scans
Authors: Timothy J. P. Bray, Andre Lopes, Corinne Fisher, Coziana Ciurtin, Debajit Sen, Margaret A. Hall‐Craggs
Journal: Arthritis & Rheumatology (2018)

To assess the temporal relationship between initiating biologic therapy and magnetic resonance imaging (MRI) scores of inflammation and structural damage in young patients with spondyloarthritis.A local adolescent/young adult patient rheumatology database was searched for patients ages 12-24 years who had evidence of sacroiliitis on MRI and a clinical diagnosis of enthesitis-related arthritis (ERA) with axial involvement or nonradiographic axial spondyloarthritis. Patients treated with tumor necrosis factor inhibitor (TNFi) therapy who had undergone a minimum of 1 MRI scan before and 2 MRI scans after starting TNFi therapy (over ≥2 years) were included. Images of the sacroiliac joints were scored for inflammation and structural abnormalities (including erosions, fat metaplasia, and fusion). The effects of TNFi therapy and of time since initiation of TNFi therapy on inflammation and structural abnormalities were assessed using a mixed-effects regression analysis.Twenty-nine patients (ages 12-23 years) with ERA or nonradiographic axial spondyloarthritis who underwent TNFi therapy were included. Inflammation scores were significantly lower in patients receiving TNFi treatment (P = 0.013), but there was no significant effect of time from TNFi initiation on inflammation (P = 0.125). Conversely, there was no significant effect of active TNFi treatment on fusion scores (P = 0.308), but fusion scores significantly increased with time from TNFi initiation (P < 0.001); a similar positive relationship between time since biologic start and fat metaplasia scores was observed.TNFi therapy failed to prevent the eventual development of joint ankylosis in this cohort of young patients with spondyloarthritis, despite a substantial reduction in inflammation with TNFi therapy.
GW29-e0711 Pre-arrest hypothermia ameliorate the myocardial mitochondrial injury to improve the cardiac function of rats after cardiopulmonary resuscitation
Authors: Xuan Dai, Yuanzheng Lu, Xiaoyun Zeng, Hongyan Wei, Meixian Yin, Xiaoxing Liao, Chunlin Hu
Journal: Journal of the American College of Cardiology (2018)
Phase I study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors
Authors: N. Yamamoto, Y. Fujiwara, S. Kondo, S. Iwasa, K. Yonemori, A. Shimomura, S. Kitano, T. Shimizu, T. Koyama, T. Ebata, N. Sato, K. Nakai, M. Inatani, K. Tamura
Journal: Annals of Oncology (2018)
P3.16-03 Uncommon EGFR Mutations as a Worse Prognostic Factor for Surgically Resected Lung Adenocarcinoma
Authors: K. Hayasaka, S. Shiono, Y. Matsumura, H. Suzuki, N. Yanagawa, J. Abe, M. Sagawa, A. Sakurada, M. Katahira, S. Takahashi, M. Endoh, Y. Okada
Journal: Journal of Thoracic Oncology (2018)
An expression signature characterizes cancer stem cells from lung adenocarcinoma patients
Authors: A. Herreros-Pomares, S. Calabuig Fariñas, J.D. de Maya, E. Escorihuela, E. Durendez-Saez, A. Blasco Cordellat, A. Navarro, E. García-Del-Olmo, R. Lucas, R. Farràs, E. Jantus-Lewintre, C. Camps
Journal: Annals of Oncology (2018)
Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming
Authors: Marina Koutsioumpa, Maria Hatziapostolou, Christos Polytarchou, Ezequiel J Tolosa, Luciana L Almada, Swapna Mahurkar-Joshi, Jennifer Williams, Ana Belen Tirado-Rodriguez, Sara Huerta-Yepez, Dimitrios Karavias, Helen Kourea, George A Poultsides, Kevin Struhl, David W Dawson, Timothy R Donahue, Martín E Fernández-Zapico, Dimitrios Iliopoulos
Journal: Gut (2018)

Objective Despite advances in the identification of epigenetic alterations in pancreatic cancer, their biological roles in the pathobiology of this dismal neoplasm remain elusive. Here, we aimed to characterise the functional significance of histone lysine methyltransferases (KMTs) and demethylases (KDMs) in pancreatic tumourigenesis. Design DNA methylation sequencing and gene expression microarrays were employed to investigate CpG methylation and expression patterns of KMTs and KDMs in pancreatic cancer tissues versus normal tissues. Gene expression was assessed in five cohorts of patients by reverse transcription quantitative-PCR. Molecular analysis and functional assays were conducted in genetically modified cell lines. Cellular metabolic rates were measured using an XF24-3 Analyzer, while quantitative evaluation of lipids was performed by liquid chromatography-mass spectrometry (LC-MS) analysis. Subcutaneous xenograft mouse models were used to evaluate pancreatic tumour growth in vivo. Results We define a new antitumorous function of the histone lysine (K)-specific methyltransferase 2D (KMT2D) in pancreatic cancer. KMT2D is transcriptionally repressed in human pancreatic tumours through DNA methylation. Clinically, lower levels of this methyltransferase associate with poor prognosis and significant weight alterations. RNAi-based genetic inactivation of KMT2D promotes tumour growth and results in loss of H3K4me3 mark. In addition, KMT2D inhibition increases aerobic glycolysis and alters the lipidomic profiles of pancreatic cancer cells. Further analysis of this phenomenon identified the glucose transporter SLC2A3 as a mediator of KMT2D-induced changes in cellular, metabolic and proliferative rates. Conclusion Together our findings define a new tumour suppressor function of KMT2D through the regulation of glucose/fatty acid metabolism in pancreatic cancer.
Abstract 18482: Genetic and Pharmacologic Inhibition of Trem-1 Limits the Development of Experimental Atherosclerosis
Authors: Jérémie Joffre, Stephane Potteaux, Lynda Zeboudj, Xavier Loyer, Alain Tedgui, Ziad Mallat, Sebastien Gibot, Hafid Ait Oufella
Journal: Circulation (2016)

Background: Innate immune responses activated through myeloid cells contribute to the initiation, progression and complications of atherosclerosis in experimental models. However, the critical upstream pathways that link innate immune activation to foam cell formation are still poorly identified. We hypothesized that activation of TREM (Triggering Receptor Expressed on Myeloid cells)-1 plays a determinant role in macrophage atherogenic responses. Methods and Results: Ldlr-/- mice reconstituted with bone marrow deficient for Trem-1 (Trem-1-/-) showed a strong reduction of atherosclerotic plaque size in both the aortic sinus and the thoraco-abdominal aorta, and displayed a less inflammatory plaque phenotype compared to Trem-1+/+ chimeric mice. Genetic invalidation of Trem-1 led to alteration of monocyte recruitment into atherosclerotic lesions and inhibited Tlr4-initiated pro-inflammatory macrophage responses. Furthermore, we identified a critical role for Trem-1 in the upregulation of Cd36, thereby promoti...
Abstract 20487: Hydrogel-based X-ray-visible Microspheres Development for Bariatric Arterial Embolization to Treat Obesity
Authors: Yingli Fu, Charles Hu, Clifford Weiss, Hai-Quan Mao, Christos Georgiades, Dara L Kraitchman
Journal: Circulation (2016)

Introduction: Embolization particles are used to arrest blood flow in targeted arteries, commonly to mitigate bleeding or result in ischemic tumor death. Recently, embolization particles have been ...
Global epidemiology of use of and disparities in caesarean sections
Authors: Ties Boerma, Carine Ronsmans, Dessalegn Y Melesse, Aluisio J D Barros, Fernando C Barros, Liang Juan, Ann-Beth Moller, Lale Say, Ahmad Reza Hosseinpoor, Mu Yi, Dácio de Lyra Rabello Neto, Marleen Temmerman
Journal: The Lancet (2018)
Clinical characteristics and outcomes of non-small cell lung cancer (NSCLC) patients harboring MET exon 14 splice sites mutations
Authors: P. JAMME, F. Escande, C. Descarpentries, M.C. Copin, E. Dansin, T. Vanparis, D. Tulasne, S. Baldacci, Z. Kherrouche, A. Cortot
Journal: Annals of Oncology (2018)
Poor Adherence to Guidelines for Treatment of Chronic Hepatitis B Virus Infection at Primary Care and Referral Practices
Authors: Vy H. Nguyen, An K. Le, Huy N. Trinh, Mimi Chung, Tiffani Johnson, Christopher Wong, Clifford Wong, Jian Zhang, Jiayi Li, Brian S. Levitt, Huy A. Nguyen, Khanh K. Nguyen, Linda Henry, Ramsey Cheung, Mindie H. Nguyen
Journal: Clinical Gastroenterology and Hepatology (2018)
Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety
Authors: Wei Wei, Pei‐En Jian, Shao‐Hua Li, Zhi‐Xing Guo, Yong‐Fa Zhang, Yi‐Hong Ling, Xiao‐Jun Lin, Li Xu, Ming Shi, Lie Zheng, Min‐Shan Chen, Rong‐Ping Guo
Journal: Cancer Communications (2018)

Abstract Background The optimal strategy for adjuvant therapy after curative resection for hepatocellular carcinoma (HCC) patients with solitary tumor and microvascular invasion (MVI) is controversial. This trial evaluated the efficacy and safety of adjuvant transcatheter arterial chemoembolization (TACE) after hepatectomy versus hepatectomy alone in HCC patients with a solitary tumor ≥ 5 cm and MVI. Methods In this randomized, open‐labeled, phase III trial, HCC patients with a solitary tumor ≥ 5 cm and MVI were randomly assigned (1:1) to receive either 1–2 cycles of adjuvant TACE after hepatectomy (Hepatectomy‐TACE) or hepatectomy alone (Hepatectomy Alone). The primary endpoint was disease‐free survival (DFS); the secondary endpoints included overall survival (OS) and adverse events. Results Between June 1, 2009, and December 31, 2012, 250 patients were enrolled and randomly assigned to the Hepatectomy‐TACE group ( n = 125) or the Hepatectomy Alone group ( n = 125). Clinicopathological characteristics were balanced between the two groups. The median follow‐up time from randomization was 37.5 months [interquartile range 18.3–48.2 months]. The median DFS was significantly longer in the Hepatectomy‐TACE group than in the Hepatectomy Alone group [17.45 months (95% confidence interval [CI] 11.99–29.14) vs. 9.27 months (95% CI 6.05–13.70), hazard ratio [HR] = 0.70 (95% CI 0.52–0.95), P = 0.020], respectively. The median OS was also significantly longer in the Hepatectomy‐TACE group than in the Hepatectomy Alone group [44.29 months (95% CI 25.99–62.58) vs. 22.37 months (95% CI 10.84–33.91), HR = 0.68 (95% CI 0.48–0.97), P = 0.029]. Treatment‐related adverse events were more frequently observed in the Hepatectomy‐TACE group, although these were generally mild and manageable. The most common grade 3 or 4 adverse events in both groups were neutropenia and liver dysfunction. Conclusion Hepatectomy followed by adjuvant TACE is an appropriate option after radical resection in HCC patients with solitary tumor ≥ 5 cm and MVI, with acceptable toxicity.
Abstract IA08: Epigenetic mechanisms of resistance to targeted therapy
Authors: Rani E. George
Journal: Cancer Research (2018)

Abstract Targeted cancer therapies, such as inhibitors of the ALK receptor tyrosine kinase, have yielded promising outcomes in patients whose tumors aberrantly express ALK, yet the development of resistance invariably limits their efficacy. To address this issue, we have investigated potential mechanisms of resistance to ALK inhibitors in neuroblastoma cells expressing ALK point mutations. In tumor cells expressing the ALKF1174L mutant kinase in the absence of MYCN amplification, we observed that resistance to ALK inhibitors develops through activation of MAPK signaling and induction of epithelial-to-mesenchymal transition. By contrast, in tumor cells expressing the same mutation but with concomitant MYCN overexpression due to genomic amplification, resistance arises through a different mechanism, characterized by extensive chromatin remodeling and conversion to a stem cell-like state. I will describe our latest insights into the molecular details underlying this latter mechanism with emphasis on transcriptional regulators. Citation Format: Rani E. George. Epigenetic mechanisms of resistance to targeted therapy [abstract]. In: Proceedings of the AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; 2017 Dec 3-6; Atlanta, Georgia. Philadelphia (PA): AACR; Cancer Res 2018;78(19 Suppl):Abstract nr IA08.
P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients
Authors: L. Mezquita, S. Ponce Aix, E. Auclin, A. Navarro, D. Planchard, I. Sullivan, G. Zalcman, J. Mazieres, L. Hendriks, C. Caramella, M. Majem, P. Lavaud, F. Aboubakar Nana, E. Felip, L. Paz-Ares, B. Besse
Journal: Journal of Thoracic Oncology (2018)
The Persistent Problem of Overuse of Diagnostic Testing Among House Staff—Time to Move Forward
Authors: Rita F. Redberg
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement
Authors: Apostolia M. Tsimberidou, Laura A. Levit, Richard L. Schilsky, Steven D. Averbuch, Daniel Chen, John M. Kirkwood, Lisa M. McShane, Elad Sharon, Kathryn F. Mileham, Michael A. Postow
Journal: Journal of Clinical Oncology (2018)

Purpose To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments. Methods ASCO and the Society for Immunotherapy of Cancer (SITC) convened a working group that consisted of practicing medical oncologists, immunologists, clinical researchers, biostatisticians, and representatives from industry and government to develop Trial Reporting in Immuno-Oncology (TRIO) recommendations. These recommendations are based on expert consensus, given that existing data to support evidence-based recommendations are limited. Conclusion The TRIO recommendations are intended to improve the reporting of IO clinical trials and thus provide more complete evidence on the relative benefits and risks of an IO therapeutic approach. Given the rapid expansion of the number of IO clinical trials and ongoing improvements to the evidence base supporting the use of IO treatments in clinical care, these recommendations will likely need regular revision as the IO field develops.
A phase I study of HERV-E TCR transduced autologous T Cells (HERV-E TCR T Cells) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)
Authors: R. Nadal, E. Cherkasova, S. Barisic, D. Granadier, G. Aue, B. Wells, G. Hawks, T. Hughes, R. Shalabi, D. Stroncek, S. Highfill, G. Scurti, L. Chen, R. Reger, M. Nishimura, R. Childs
Journal: Annals of Oncology (2018)
Abstract P306: Negative Emotional States and Atherosclerosis in African American Adults: The Jackson Heart Study
Authors: Waynesha E Blaylock, Wendy B White, Alan Morrison, Mario Sims, Wen-Chih Wu
Journal: Circulation (2018)

Background: Atherosclerotic cardiovascular disease is prevalent among African Americans (AAs). Findings are mixed regarding the relationship between anger expression and peripheral atherosclerosis, as well as coronary atherosclerosis, as measured by coronary artery calcification (CAC). In addition, this relationship is unknown among AAs. Hypothesis: Higher anger levels are positively associated with CAC and abdominal-iliac artery calcification (AAC) among AAs. Methods: Using the Jackson Heart Study cohort (N=5301), we stratified 1809 participants who completed the Spielberger Anger Expression scale at baseline into four quartiles. The scale consists of 16 items, measuring anger-in and anger-out, with higher scores representing higher frequencies of anger expression. Total anger (anger-in and anger-out) quartiles were measured against CAC and AAC using ordinal logistic regression. CAC and AAC were categorized as: 0, 1-10, 11-100, 101-300, and greater than 300. Models were adjusted for potential confounding variables (age, sex, smoking, alcohol, diabetes mellitus, hypertension, and coronary heart disease). Results: The final study sample consisted of 34% (615 of 1809) male with a mean age of 54.0 (SD 10.79). Higher total anger was inversely associated with age and hypertension, but positively related to alcohol use and smoking status. Unadjusted analysis showed that total anger quartiles and anger-in quartiles were inversely related to CAC and AAC. The association of anger with CAC and AAC was non-significant after adjustment for confounders (Table). Conclusion: Before adjustment, higher anger levels showed a protective effect against coronary and aortic atherosclerosis. However, this relationship was no longer significant after adjustment for confounders suggesting that age and hypertension played a major role in the presence of atherosclerosis in this AA population. Future studies should investigate whether other negative emotional expressions are associated with atherosclerosis in AAs
Association of social deprivation with 1-year outcome of ICU survivors: results from the FROG-ICU study
Authors: Kathleen Bastian, Alexa Hollinger, Alexandre Mebazaa, Elie Azoulay, Elodie Féliot, Karine Chevreul, Marie-Céline Fournier, Bertrand Guidet, Morgane Michel, Philippe Montravers, Sébastien Pili-Floury, Romain Sonneville, Martin Siegemund, Etienne Gayat
Journal: Intensive Care Medicine (2018)
Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study
Authors: Y. Loriot, A. Necchi, S.H. Park, R.A. Huddart, E. Burgess, B. Zhong, A. Santiago-Walker, S. Little, T. Roccia, P. De Porre, A.O. Siefker-Radtke
Journal: Annals of Oncology (2018)
GW29-e1642 Single cell engineering with surface-conjugated gelatin improves mechenchymal stem cell survival and therapeutic effects for heart repair
Authors: Ling Zhang, Xinyang Hu, Kaiqi Lv, Changchen Xiao, Yinchao Wang, Jing Zhao, Keyang Zhu, Jianan Wang
Journal: Journal of the American College of Cardiology (2018)
Molecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES study
Authors: F. Zanelli, M. Pagano, C. Bonelli, R. Gnoni, L. Boni, G.L. Ceresoli, M. Larocca, M. Tiseo, P. Zucali, F. Grosso, F. Cappuzzo, A. Ciarrocchi, F. Torricelli, C. Pinto
Journal: Annals of Oncology (2018)
Development of polyurethane foam dressing containing silver and asiaticoside for healing of dermal wound
Authors: Nantaporn Namviriyachote, Vimolmas Lipipun, Yada Akkhawattanangkul, Phingphol Charoonrut, Garnpimol C. Ritthidej
Journal: Asian Journal of Pharmaceutical Sciences (2018)

Polyurethane foam dressings for dermal wounds were formulated with natural polyols in order to improve the foam characteristics and the release of 2 active agents, silver and asiaticoside (AS) as an antimicrobial agent and an herbal wound healing agent, respectively. The foam was instantly formed by interaction of polyols and diisocyanate. Hydroxypropyl methylcellulose, chitosan and sodium alginate were individually mixed with the main polyols, polypropylene glycol, in the formulation while the active components were impregnated into the obtained foam dressing sheets. Although the type and amount of the natural polyols slightly affected the pore size, water sorption-desorption profile and compression strength of the obtained foam sheets, a prominent effect was found in the release of both active components. Among natural polyols formulations, foam sheets with alginate showed the highest silver and AS release. Non-cytotoxicity of these foam sheets to human fibroblast cells was confirmed. Antimicrobial testing on four bacteria strains showed that 1 mg/cm2 silver in formulations with 6% of natural polyols and without natural polyols had sufficient content of the silver release with comparable inhibition zone and significantly larger zone than other formulations. In pig study, the foam dressing with 6% alginate, 1 mg/cm2 silver and 5% AS could improve wound healing in both the percentage of the wound closure and histological parameters of the dermal wound without any dermatologic reactions. In conclusion, this innovative foam dressing had potential to be a good candidate for wound treatment.
EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)
Authors: D.P. Petrylak, J. Rosenberg, I. Duran, Y. Loriot, G. Sonpavde, C. Wu, E. Gartner, A. Melhem-Bertrandt, T. Powles
Journal: Annals of Oncology (2018)
Micropatterned Scaffolds with Immobilized Growth Factor Genes Regenerate Bone and Periodontal Ligament‐Like Tissues
Authors: Sophia P. Pilipchuk, Tobias Fretwurst, Ning Yu, Lena Larsson, Nolan M. Kavanagh, Farah Asa'ad, Kenneth C. K. Cheng, Joerg Lahann, William V. Giannobile
Journal: Advanced Healthcare Materials (2018)

Abstract Periodontal disease destroys supporting structures of teeth. However, tissue engineering strategies offer potential to enhance regeneration. Here, the strategies of patterned topography, spatiotemporally controlled growth factor gene delivery, and cell‐based therapy to repair bone–periodontal ligament (PDL) interfaces are combined. Micropatterned scaffolds are fabricated for the ligament regions using polycaprolactone (PCL)/polylactic‐ co ‐glycolic acid and combined with amorphous PCL scaffolds for the bone region. Scaffolds are modified using chemical vapor deposition, followed by spatially controlled immobilization of vectors encoding either platelet‐derived growth factor‐BB or bone morphogenetic protein‐7, respectively. The scaffolds are seeded with human cells and delivered to large alveolar bone defects in athymic rats. The effects of dual and single gene delivery with and without micropatterning are assessed after 3, 6, and 9 weeks. Gene delivery results in greater bone formation at three weeks. Micropatterning results in regenerated ligamentous tissues similar to native PDL. The combination results in more mature expression of collagen III and periostin, and with elastic moduli of regenerated tissues that are statistically indistinguishable from those of native tissue, while controls are less stiff than native tissues. Thus, controlled scaffold microtopography combined with localized growth factor gene delivery improves the regeneration of periodontal bone–PDL interfaces.